What is more, the authors demonstrated that SLAMF3/CD229 is naturally processed and presented as a tumor-associated antigen in primary CLL B cells (unstimulated or CD40L-stimulated). This evidence concerns the gene LY9 and B-cell chronic lymphocytic leukemia.